CA3046320A1 - Novel cannabinoid compositions and methods of treating epilepsy - Google Patents

Novel cannabinoid compositions and methods of treating epilepsy Download PDF

Info

Publication number
CA3046320A1
CA3046320A1 CA3046320A CA3046320A CA3046320A1 CA 3046320 A1 CA3046320 A1 CA 3046320A1 CA 3046320 A CA3046320 A CA 3046320A CA 3046320 A CA3046320 A CA 3046320A CA 3046320 A1 CA3046320 A1 CA 3046320A1
Authority
CA
Canada
Prior art keywords
cbd
composition
day
thc
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3046320A
Other languages
English (en)
French (fr)
Inventor
Catherine JACOBSON
Caleb Joshua Eades
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tilray Brands Inc
Original Assignee
Tilray Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tilray Inc filed Critical Tilray Inc
Publication of CA3046320A1 publication Critical patent/CA3046320A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/348—Cannabaceae
    • A61K36/3482—Cannabis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Neurology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pyrane Compounds (AREA)
CA3046320A 2016-12-20 2017-12-20 Novel cannabinoid compositions and methods of treating epilepsy Pending CA3046320A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662436861P 2016-12-20 2016-12-20
US62/436,861 2016-12-20
PCT/IB2017/001683 WO2018115962A1 (en) 2016-12-20 2017-12-20 Novel cannabinoid compositions and methods of treating pediatric epilepsy

Publications (1)

Publication Number Publication Date
CA3046320A1 true CA3046320A1 (en) 2018-06-28

Family

ID=61028091

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3046320A Pending CA3046320A1 (en) 2016-12-20 2017-12-20 Novel cannabinoid compositions and methods of treating epilepsy

Country Status (12)

Country Link
US (1) US20200215022A1 (enExample)
EP (1) EP3558297A1 (enExample)
JP (2) JP2020514282A (enExample)
KR (1) KR20190099221A (enExample)
AU (1) AU2017381587A1 (enExample)
BR (1) BR112019012776A2 (enExample)
CA (1) CA3046320A1 (enExample)
CL (1) CL2019001668A1 (enExample)
CO (1) CO2019006911A2 (enExample)
MX (1) MX2019007496A (enExample)
PE (1) PE20200338A1 (enExample)
WO (1) WO2018115962A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11622956B1 (en) 2019-06-26 2023-04-11 RCR BioPharma Compound and method for treating diseases and disorders

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2531282A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy
GB2539472A (en) 2015-06-17 2016-12-21 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
GB2568929A (en) 2017-12-01 2019-06-05 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
GB201806953D0 (en) 2018-04-27 2018-06-13 Gw Res Ltd Cannabidiol Preparations
IL261132A (en) * 2018-08-13 2018-11-04 Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd Formulated cannabis oil powder by nanoemulsifycation, methods of producing and uses thereof
GB2580653A (en) * 2019-01-21 2020-07-29 Gw Res Ltd Use of cannabinoids in the treatment of comorbidities associated with epilepsy
EP3931330A4 (en) 2019-02-25 2023-03-15 Ginkgo Bioworks, Inc. BIOSYNTHESIS OF CANNABINOIDS AND CANNABINOID PRECURSORS
GB202009321D0 (en) 2020-06-18 2020-08-05 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
GB2598922A (en) 2020-09-18 2022-03-23 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
CA3217137A1 (en) 2021-04-29 2022-11-03 Christopher Adair Cannabidiol-dominant formulations, methods of manufacturing, and uses thereof
WO2023047308A1 (en) * 2021-09-22 2023-03-30 Avicanna Inc. Methods for reducing or eliminating incidence of seizures and sudden unexpected death in epilepsy
WO2023200906A1 (en) 2022-04-12 2023-10-19 Shackelford Pharma Inc. Treatment of seizure disorders

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1361864T3 (en) * 2001-02-14 2014-03-03 Gw Pharma Ltd FLYLDENDE SPRAY FORMULATIONS FOR buccal administration of cannabinoids
GB2530001B (en) * 2014-06-17 2019-01-16 Gw Pharma Ltd Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy
GB2531282A (en) * 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy
CA2970651C (en) * 2014-12-12 2020-09-29 Ojai Energetics Pbc Microencapsulated cannabinoid compositions
BR112017018944A2 (en) * 2015-03-02 2018-05-15 Afgin Pharma, Llc method of treating a disease state or condition in humans with a carbinoid drug, and method of treating a disease state or condition in a mammal other than a human with carbinoid drug (s)
WO2017137992A1 (en) * 2016-02-11 2017-08-17 Gelpell Ag Oral solid cannabinoid formulations, methods for producing and using thereof

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11622956B1 (en) 2019-06-26 2023-04-11 RCR BioPharma Compound and method for treating diseases and disorders
US11759447B1 (en) 2019-06-26 2023-09-19 RCR BioPharma Compound and method for treating diseases and disorders

Also Published As

Publication number Publication date
EP3558297A1 (en) 2019-10-30
KR20190099221A (ko) 2019-08-26
BR112019012776A2 (pt) 2019-12-10
CO2019006911A2 (es) 2019-08-30
PE20200338A1 (es) 2020-02-14
US20200215022A1 (en) 2020-07-09
MX2019007496A (es) 2019-10-30
AU2017381587A1 (en) 2019-06-20
JP2023001138A (ja) 2023-01-04
JP2020514282A (ja) 2020-05-21
CL2019001668A1 (es) 2019-09-06
WO2018115962A1 (en) 2018-06-28

Similar Documents

Publication Publication Date Title
JP2023001138A (ja) 新規カンナビノイド組成物および使用方法
AU2019297198B2 (en) Composition and method for treating pain
CN101939017B (zh) 大麻素在与抗精神病药物组合中的用途
EP3215148B1 (en) Use of low dose of tetrahydrocannabinol for the treatment of cognitive decline in elderly patients
US20200276155A1 (en) Composition and method for treating autism
WO2019224824A1 (en) Cannabis-based compositions for the treatment of autistic spectrum disorders
AU2021215262B2 (en) Composition and method for treating chronic pain
US20190091198A1 (en) Cannabionid and cannabis-based compositions and methods for the treatment of inflammatory conditions of the gastrointestinal tract
US20240024340A1 (en) Compositions and Methods For Treating Migraine
AU2018100928A4 (en) Composition and method for opioid sparing
WO2020188568A1 (en) Methods and compositions for treating autism spectrum disorder and associated disorders
WO2020183455A1 (en) Cannabinoid combinations for treating low back pain
RS65144B1 (sr) Postupak za lečenje prader-vilijevog sindroma
Gupta et al. Valbenazine for the treatment of adults with tardive dyskinesia
AU2021390590B2 (en) Antiinflammatory compositions comprising cannabidiol, delta-9- tetrahydrocannabinol and linalool
CA2612019A1 (en) Dronabinol treatment for migraines
WO2021077108A1 (en) Method of treating autism
WO2022049581A1 (en) Composition comprising cannabinoids, and/or terpens, and methods of using same
WO2020188569A1 (en) Methods and compositions for preventing or treating weight gain caused by psychiatric drugs
AU2021106137A4 (en) Composition and method for treating chronic pain
WO2025038586A1 (en) Composition of cannabinoid extract of cw1as1 for the treatment of autism and associated symptoms
JP2024539429A (ja) 閉経後症状の治療におけるウィタニア・ソムニフェラ及びアスパラガス・ラセモサス
Harshit Gupta et al. Valbenazine for the Treatment of Adults with Tardive Dyskinesia
Allen et al. Does phentermine use for weight loss have significant adverse effects?

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220929

N11 Application terminated

Free format text: ST27 STATUS EVENT CODE: T-6-6-N10-N11-N106 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION NOT REINSTATED BY DEADLINE

Effective date: 20250620

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251229

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260203